期刊文献+

PreS-Tat真核表达载体的构建及表达

Construction and expression of eukaryotic vector encoding PreS-Tat
下载PDF
导出
摘要 目的:构建pEGFP-PreS-Tat嵌合载体并在真核细胞中表达。方法:提取人乙型肝炎病毒并用PCR法扩增出PreS片段,定向克隆入pEGFP-C3载体,在PreS下游连接合成的Tat序列,构建成功的pEGFP-PreS-Tat质粒经脂质体转染Hela细胞,Westernblot鉴定目的蛋白的表达。结果:酶切和测序结果表明成功地构建了pEGFP-PreS-Tat嵌合载体,WesternBlot结果表明该载体能在Hela细胞中表达pEGFP-PreS-Tat融合蛋白。结论:成功构建pEG-FP-PreS-Tat载体并表达出相应的融合蛋白,为研究该融合蛋白的功能奠定了基础。 Aim:To construct the chimeric vector PreS-Tat and express it in the eukaryotic cells.Methods:After amplifying the HBV PreS gene,the products were cloned into the pEGFP-C3 vector.The synthetic Tat sequences were inserted into the downstream of the PreS.The resultant recombinant vectors were transfected into eukaryotic cell Hela by lipofectamine.Western blot was used to certify the purpose protein.Results:The recombinant plasmid was confirmed by restriction endonuclease and sequencing.The pEGFP-PreS-Tat fusion protein was successfully expressed in the Hela cells.Conclusion:pEGFP-PreS-Tat has been constructed and the fusion protein is expressed successfully,which lays the foundation for studying the functions of the protein.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2011年第5期706-709,共4页 Journal of Zhengzhou University(Medical Sciences)
基金 国家自然科学基金资助项目30472031
关键词 PRES TAT 乙型肝炎病毒 蛋白转导区 PreS Tat hepatitis B virus protein transduction domain
  • 相关文献

参考文献9

  • 1Loomba R,Liang TJ. Novel approaches to new therapies for hepatitis B virus infection[ J]. Antivir Ther, 2006,11 (1) : 1.
  • 2Lavanchy D. Hepatitis B virus epidemiology, disease bur- den, treatment, and current and emerging prevention and control measures [ J ]. J Viral Hepat,2004,11 ( 2 ) : 97.
  • 3Lin Y, Liu YX, Cislo T,et al. Expression and character- ization of the preS1 peptide of hepatitis B surface antigen in Escherichia coli[ J]. J Med Virol,1991,33(3) :181.
  • 4Tang KH, Yusoff K, Tan WS. Display of hepatitis B virus PreS1 peptide on bacteriophage T7 and its potential in gene delivery into HepG2 ceils [ J ]. J Virol Methods, 2009,159 (2) :194.
  • 5Miyata R, Ueda M, Jinno H, et al. Selective targeting by preS1 domain of hepatitis B surface antigen conjugated with phosphorylcholine-based amphiphilic block copolymer mi- celles as a biocompatible, drug delivery carrier for treat-ment of human hepatocellular carcinoma with paclitaxel [J]. Int J Cancer,2009,124(10) :2460.
  • 6Oess S,Hildt E. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens[ J]. Gene Ther, 2000,7(9) :750.
  • 7Yamauchi K, Nakamura T, Yonemitsu H, et al. Possible role of preS2 peptides presented by MHC class I antigen in the pathogenesis of chronic hepatitis B[ J ]. J Hepatol, 1993, 17(Suppl 3) :S6.
  • 8Madalinski K, Sylvan SP, Hellstrom U, et al. Presence of anti-preS1, anti-preS2, and anti-HBs antibodies in newbo- rns immunized with Bio-Hep-B vaccine [ J ]. Med Sci Monit,2004,10( 1 ) :P110.
  • 9Eum WS, Choung IS, Li MZ, et al. HIV-1 Tat-mediated protein transduction of Cu, Zn-superoxide dismutase into pancreatic beta cells in vitro and in vivo [ J ]. Free Radic Biol Med, 2004,37(3) :339.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部